All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-09-17T10:34:40.000Z

Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.

By Erika Roa, Mark Maitland, Addy Dullaghan
Featured
Pieter Sonneveld
Sep 17, 2021
Share:

Bookmark this article

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, Why the initial efficacy observed with melflufen + dexamethasone has not translated into improved overall survival (OS) in the OCEAN phase III trial.

OCEAN phase III trial: Why the initial efficacy observed with melflufen + dex has not improved OS

In this video, Sonneveld discusses results from the OCEAN phase III (NCT03151811), multi-center trial, comparing melphalan flufenamide (melflufen) + dexamethasone versus pomalidomide + dexamethasone.

 

More about...
DexamethasoneIMWIMW 2021MelflufenOCEANRelapsed/refractory multiple myeloma

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
27 votes - 6 days left ...

Related articles

Add bookmark

OCEAN subgroup analysis: Melflufen in patients refractory to prior alkylators

Here, we summarize a post hoc analysis investigating the effects of refractoriness to standard-dose prior alkylators on the effectiveness of melflufen + dexamethasone on a...

Mar 15, 2024
Add bookmark

OCEAN subgroup analysis: Melflufen in patients refractory to prior alkylators

Here, we summarize a post hoc analysis investigating the effects of refractoriness to standard-dose prior alkylators on...

Mar 15, 2024
Add bookmark

Priority Review of melflufen for patients with triple-class refractory MM by FDA

The first-in-class peptide–drug conjugate melphalan flufenamide, also known as melflufen (MF), in combination with dexamethasone is to receive priority review by the...

Sep 4, 2020
Add bookmark

Priority Review of melflufen for patients with triple-class refractory MM by FDA

The first-in-class peptide–drug conjugate melphalan flufenamide, also known as melflufen (MF), in combination with...

Sep 4, 2020

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox